{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:33:39Z","timestamp":1793968419035,"version":"4.8.0"},"reference-count":16,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,2,10]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>Trastuzumab-deruxtecan (T-DXd) is a novel antibody drug conjugate that has improved treatment outcomes in patients with ERBB2-positive cancer, including locally advanced or metastatic gastric and gastro-oesophageal junction adenocarcinoma. One of the reported side effects of this medication is drug-induced pneumonitis. We present in this case report, a diagnostic dilemma of a patient presenting with clinical and radiographical features of drug-induced pneumonitis but was found to have pneumocystis jirovecii pneumonia (PJP). Our case is the first of PJP in a patient treated with T-DXd, highlighting the increasing incidence of this opportunistic infection in patients with solid malignancy. It also highlights the clinical and radiographical similarities between the PJP and drug-induced pneumonitis.<\/jats:p>","DOI":"10.1136\/bcr-2022-253647","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T09:50:10Z","timestamp":1676886610000},"page":"e253647","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Pneumocystis jirovecii pneumonia in a patient treated with trastuzumab-deruxtecan"],"prefix":"10.1136","volume":"16","author":[{"given":"Haneen","family":"Mallah","sequence":"first","affiliation":[{"name":"Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellery","family":"Altshuler","sequence":"additional","affiliation":[{"name":"Internal Medicine, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Ramnaraign","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Universitry of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Khawaja","sequence":"additional","affiliation":[{"name":"Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"2025082700082274000_16.2.e253647.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31774-X"},{"key":"2025082700082274000_16.2.e253647.2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab deruxtecan: first approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"2025082700082274000_16.2.e253647.3","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-022-01736-w","article-title":"Trastuzumab deruxtecan-induced interstitial lung disease\/pneumonitis in ErbB2-positive advanced solid malignancies: a systematic review","volume":"82","author":"Abuhelwa","year":"2022","journal-title":"Drugs"},{"key":"2025082700082274000_16.2.e253647.4","unstructured":"Enhertu.prescribing information. n.d. Available: https:\/\/daiichisankyo.us\/prescribing-information-portlet\/getPIContent?productName=Enhertu&inline=true"},{"key":"2025082700082274000_16.2.e253647.5","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-08727-2","article-title":"Clinical characteristics and risk factors associated with Pneumocystis jirovecii infection in patients with solid tumors: study of Thirteen-year medical records of a large cancer center","volume":"21","author":"Takeda","year":"2021","journal-title":"BMC Cancer"},{"key":"2025082700082274000_16.2.e253647.6","unstructured":"National Cancer Institute, National Institutes of Health, US Department of Health and Human Services . Common terminology criteria for adverse events (CTCAE), version 5.0. NIH. published nov 27. 2017."},{"key":"2025082700082274000_16.2.e253647.7","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-ErbB2 antibody-drug conjugates: a review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025082700082274000_16.2.e253647.8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejrad.2019.04.025","article-title":"Pneumocystis jirovecii pneumonia at chest high-resolution computed tomography (HRCT) in non-HIV immunocompromised patients: spectrum of findings and mimickers","volume":"116","author":"Cereser","year":"2019","journal-title":"Eur J Radiol"},{"key":"2025082700082274000_16.2.e253647.9","doi-asserted-by":"publisher","DOI":"10.1177\/1078155211412991"},{"key":"2025082700082274000_16.2.e253647.10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1177\/10781552211066073","article-title":"Pneumonitis associated with trastuzumab emtansine in a patient with metastatic breast cancer","volume":"28","author":"U\u011frakl\u0131","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"2025082700082274000_16.2.e253647.11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000326063","article-title":"Delayed paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer","volume":"4","author":"Abulkhair","year":"2011","journal-title":"Case Rep Oncol"},{"key":"2025082700082274000_16.2.e253647.12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.breast.2021.11.016","article-title":"The first reported case of trastuzumab induced interstitial lung disease associated with anti-neutrophil cytoplasmic antibody vasculitis-a case report and a prospective cohort study on the usefulness of neutrophil derived biomarkers in monitoring vasculitis disease activity during follow-up","volume":"61","author":"Chang","year":"2022","journal-title":"Breast"},{"key":"2025082700082274000_16.2.e253647.13","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1177\/1078155218813716","article-title":"Interstitial pneumonitis associated with trastuzumab emtansine","volume":"25","author":"Alkan","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"2025082700082274000_16.2.e253647.14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3892\/mco.2016.1113","article-title":"Interstitial lung disease associated with trastuzumab monotherapy: a report of 3 cases","volume":"6","author":"Sugaya","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"2025082700082274000_16.2.e253647.15","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.928","article-title":"Two cases of trastuzumab deruxtecan-induced interstitial lung disease in advanced breast cancer","volume":"10","author":"Gocho","year":"2022","journal-title":"Respirol Case Rep"},{"key":"2025082700082274000_16.2.e253647.16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijid.2022.12.027","article-title":"Pneumocystis jirovecii pneumonia in patients with decompensated cirrhosis: a case series","volume":"128","author":"Franceschini","year":"2023","journal-title":"Int J Infect Dis"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-253647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:08:38Z","timestamp":1756278518000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-253647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,20]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/bcr-2022-253647"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-253647","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}